The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Motilium     6-chloro-3-[1-[3-(2-oxo-3H- benzoimidazol-1...

Synonyms: Motinorm, Nauzelin, Motillium, Ovaprim, Domperidon, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Motilium


Psychiatry related information on Motilium


High impact information on Motilium


Chemical compound and disease context of Motilium


Biological context of Motilium


Anatomical context of Motilium


Associations of Motilium with other chemical compounds


Gene context of Motilium

  • Unlike GH, plasma PRL responses to domperidone infusion were not modified by the additional administration of L-dopa [25].
  • Mean plasma GH levels did not change during domperidone alone [25].
  • VIP-A infusion had no effect on the PRL secretory responses to DOM given at 1200 or 1700 h but attenuated the heightened response at 0300 h [33].
  • Twenty-six women diagnosed by dynamic tests and radiologic examination as having PRL-secreting adenoma were treated surgically (15) or with bromocriptine (11) and their condition was evaluated one to three years later by TRH, nomifensine, and domperidone tests [34].
  • Domperidone (5 and 50 microm) hydroxylation and N-dealkylation was catalyzed by expressed CYP3A4 at a higher rate than the other CYPs [35].

Analytical, diagnostic and therapeutic context of Motilium


  1. Domperidone in reflux oesophagitis and gastric stasis. Schulze-Delrieu, K., Summers, R.W., Finke, D. Lancet (1981) [Pubmed]
  2. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease. Corsini, G.U., Del Zompo, M., Gessa, G.L., Mangoni, A. Lancet (1979) [Pubmed]
  3. Sudden death in cancer patient on high-dose domperidone. Joss, R.A., Goldhirsch, A., Brunner, K.W., Galeazzi, R.L. Lancet (1982) [Pubmed]
  4. Domperidone in chronic intestinal pseudoobstruction. Turgeon, D.K. Gastroenterology (1990) [Pubmed]
  5. Gynecomastia in a male infant given domperidone. van der Steen, M., Du Caju, M.V., Van Acker, K.J. Lancet (1982) [Pubmed]
  6. A novel water-soluble dopamine-2 antagonist with anticholinesterase activity in gastrointestinal motor activity. Comparison with domperidone and neostigmine. Iwanaga, Y., Miyashita, N., Morikawa, K., Mizumoto, A., Kondo, Y., Itoh, Z. Gastroenterology (1990) [Pubmed]
  7. Delayed gastric emptying and improvement with domperidone in a patient with anorexia nervosa. Russell, D.M., Freedman, M.L., Feiglin, D.H., Jeejeebhoy, K.N., Swinson, R.P., Garfinkel, P.E. The American journal of psychiatry. (1983) [Pubmed]
  8. Impaired gastric slow waves induced by spatial disorientation and effect of domperidone. Kono, T., Tokumaru, O., Mizumoto, C., Tatsuno, J., Chen, J.D. Am. J. Gastroenterol. (1999) [Pubmed]
  9. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Patterson, D., Abell, T., Rothstein, R., Koch, K., Barnett, J. Am. J. Gastroenterol. (1999) [Pubmed]
  10. Does domperidone potentiate mirtazapine-associated restless legs syndrome? Chang, C.C., Shiah, I.S., Chang, H.A., Mao, W.C. Prog. Neuropsychopharmacol. Biol. Psychiatry (2006) [Pubmed]
  11. 3H-apomorphine labels both dopamine postsynaptic receptors and autoreceptors. Sokoloff, P., Martres, M.P., Schwartz, J.C. Nature (1980) [Pubmed]
  12. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. Schinkel, A.H., Wagenaar, E., Mol, C.A., van Deemter, L. J. Clin. Invest. (1996) [Pubmed]
  13. Altered gastric emptying and prevention of radiation-induced vomiting in dogs. Dubois, A., Jacobus, J.P., Grissom, M.P., Eng, R.R., Conklin, J.J. Gastroenterology (1984) [Pubmed]
  14. Domperidone and lactation. Hofmeyr, G.J., van Iddekinge, B. Lancet (1983) [Pubmed]
  15. A randomized comparison of metoclopramide and domperidone on plasma aldosterone concentration and on spironolactone-induced diuresis in ascitic cirrhotic patients. D'Arienzo, A., Ambrogio, G., Di Siervi, P., Perna, E., Squame, G., Mazzacca, G. Hepatology (1985) [Pubmed]
  16. Effects of metoclopramide and domperidone on blood flow in portal hypertension. Gholson, C.F., Freeman, M.R. Hepatology (1987) [Pubmed]
  17. Current concepts in diabetic gastroparesis. Smith, D.S., Ferris, C.D. Drugs (2003) [Pubmed]
  18. Carotid body chemoreceptor response to prolonged hypoxia in the rabbit: effects of domperidone and propranolol. Li, K.Y., Ponte, J., Sadler, C.L. J. Physiol. (Lond.) (1990) [Pubmed]
  19. Drug-induced movement disorders. Jiménez-Jiménez, F.J., García-Ruiz, P.J., Molina, J.A. Drug safety : an international journal of medical toxicology and drug experience. (1997) [Pubmed]
  20. Quantitative determination of dopamine receptor subtypes not linked to activation of adenylate cyclase in rat striatum. Huff, R.M., Molinoff, P.B. Proc. Natl. Acad. Sci. U.S.A. (1982) [Pubmed]
  21. Dopamine D(2) receptor activation causes mitogenesis via p44/42 mitogen-activated protein kinase in opossum kidney cells. Narkar, V.A., Hussain, T., Pedemonte, C., Lokhandwala, M.F. J. Am. Soc. Nephrol. (2001) [Pubmed]
  22. Peripheral dopaminergic blockade for the treatment of diabetic orthostatic hypotension. Lopes de Faria, S.R., Zanella, M.T., Andriolo, A., Ribeiro, A.B., Chacra, A.R. Clin. Pharmacol. Ther. (1988) [Pubmed]
  23. Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. Murray, A.M., Ryoo, H.L., Gurevich, E., Joyce, J.N. Proc. Natl. Acad. Sci. U.S.A. (1994) [Pubmed]
  24. Domperidone, an extracerebral inhibitor of dopamine receptors, stimulates thyrotropin and prolactin release in man. Delitala, G., Devilla, L., Lotti, G. J. Clin. Endocrinol. Metab. (1980) [Pubmed]
  25. Growth hormone inhibitory and stimulatory actions of L-dopa in patients with acromegaly. Hanew, K., Sasaki, A., Sato, S., Goh, M., Yoshinaga, K. J. Clin. Endocrinol. Metab. (1987) [Pubmed]
  26. Central dopaminergic origin of bromocriptine induced tachycardia in normotensive rats. Lahlou, S., Duarte, G.P., Demenge, P. Cardiovasc. Res. (1993) [Pubmed]
  27. Effect of domperidone on lower esophageal sphincter tone in late pregnancy. Brock-Utne, J.G., Downing, J.W., Dimopoulos, G.E., Rubin, J., Moshal, M.G. Anesthesiology (1980) [Pubmed]
  28. Purification of bovine striatal dopamine D-2 receptor by affinity chromatography. Ramwani, J., Mishra, R.K. J. Biol. Chem. (1986) [Pubmed]
  29. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Meier, J.J., Kemmeries, G., Holst, J.J., Nauck, M.A. Diabetes (2005) [Pubmed]
  30. Interactions of dopaminergic agonists and antagonists with dopaminergic D3 binding sites in rat striatum. Evidence that [3H]dopamine can label a high affinity agonist-binding state of the D1 dopamine receptor. Leff, S.E., Creese, I. Mol. Pharmacol. (1985) [Pubmed]
  31. The use of tegaserod in critically ill patients with impaired gastric motility. Banh, H.L., MacLean, C., Topp, T., Hall, R. Clin. Pharmacol. Ther. (2005) [Pubmed]
  32. Metoclopramide increases vasopressin secretion. Norbiato, G., Bevilacqua, M., Chebat, E., Bertora, P., Cavaiani, P., Baruto, C., Fumagalli, S., Raggi, U. J. Clin. Endocrinol. Metab. (1986) [Pubmed]
  33. Hypothalamic factors involved in the endogenous stimulatory rhythm regulating prolactin secretion. Arey, B.J., Freeman, M.E. Endocrinology (1989) [Pubmed]
  34. Prolactin secretion after surgery or bromocriptine treatment of prolactinoma. De Leo, V., Petraglia, F., Sardelli, S., Danero, S., Genazzani, A.R., D'Antona, N. Obstetrics and gynecology. (1987) [Pubmed]
  35. Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Ward, B.A., Morocho, A., Kandil, A., Galinsky, R.E., Flockhart, D.A., Desta, Z. British journal of clinical pharmacology. (2004) [Pubmed]
  36. Defective regulation of prolactin secretion after successful removal of prolactinomas. Camanni, F., Ghigo, E., Ciccarelli, E., Massara, F., Campagnoli, C., Molinatti, G., Müller, E.E. J. Clin. Endocrinol. Metab. (1983) [Pubmed]
  37. The effects of transient dopamine antagonism on thyrotropin-releasing hormone-induced prolactin release in pseudopregnant rats. Haisenleder, D.J., Moy, J.A., Gala, R.R., Lawson, D.M. Endocrinology (1986) [Pubmed]
  38. Dopamine receptors on intact anterior pituitary cells in culture: functional association with the inhibition of prolactin and thyrotropin. Foord, S.M., Peters, J.R., Dieguez, C., Scanlon, M.F., Hall, R. Endocrinology (1983) [Pubmed]
  39. A randomised double blind crossover study of domperidone and prochlorperazine suppositories for controlling emesis in outpatients receiving chemotherapy. Olver, I.N., Laidlaw, C.R., Matthews, J.P., Bishop, J.F., Hayes, A.M., Wolf, M., Toner, G.C. Eur. J. Cancer (1994) [Pubmed]
WikiGenes - Universities